AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28350519 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomethylating agents (HMAs)
Number of subjects: 1698
Study 28350519 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (LEN)
Number of subjects: 1698
Study 28350519 — intervention group
Group type: EXPERIMENTAL
Intervention: Other treatments (MISC)
Number of subjects: 1698
Study 28350519 — intervention group
Group type: COMPARATOR
Intervention: RBC transfusions only (Control)
Number of subjects: 1698
Study 26184525 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept (160mg intrabursal injection)
Number of subjects: 33
Study 26184525 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone acetonide (80mg in 6mL mixture of lidocaine and bupivacaine)
Number of subjects: 33
Study 22938910 — intervention group
Group type: EXPERIMENTAL
Intervention: Polylens Y10 (1-piece IOL)
Number of subjects: 40
Study 22938910 — intervention group
Group type: COMPARATOR
Intervention: Polylens Y30 (3-piece IOL)
Number of subjects: 40
Study 21992986 — intervention group
Group type: EXPERIMENTAL
Intervention: Expedited Partner Therapy (EPT)
Number of subjects: 0
Study 21992986 — intervention group
Group type: COMPARATOR
Intervention: Standard Partner Referral (SR)
Number of subjects: 0
Study 18182977 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 surgery (n=110)
Number of subjects: 221
Study 18182977 — intervention group
Group type: COMPARATOR
Intervention: D3 surgery (n=111)
Number of subjects: 221
Study 18182977 — intervention group
Group type: COMPARATOR
Intervention: D1 and D3 patients
Number of subjects: 221
Study 18182977 — intervention group
Group type: EXPERIMENTAL
Intervention: Total gastrectomy, advanced cancer, hemipancreaticosplenectomy
Number of subjects: 221
Study 17004900 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy protein (25 g protein, four times a week for 4 weeks)
Number of subjects: 17
Study 17004900 — intervention group
Group type: COMPARATOR
Intervention: Whey protein (control)
Number of subjects: 17
Study 14581272 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel (36 mg/m²)
Number of subjects: 71
Study 14581272 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (80 mg/m²)
Number of subjects: 71
Study 10812870 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based decision making
Number of subjects: 0
Study 10812870 — intervention group
Group type: COMPARATOR
Intervention: Experience-based decision making
Number of subjects: 0
Study 8702052 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 150 mg kg‐1 in 250 ml 5% dextrose i.v. over 30 min
Number of subjects: 30
Study 8702052 — intervention group
Group type: COMPARATOR
Intervention: Placebo in 250 ml 5% dextrose i.v. over 30 min
Number of subjects: 30
Study 1731546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine (100 mg IV) followed 1 min later by propofol (2 mg/kg)
Number of subjects: 82
Study 1731546 — intervention group
Group type: COMPARATOR
Intervention: Propofol (2 mg/kg IV)
Number of subjects: 82
Study 1731546 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine administered after a tourniquet inflated to 50 mm Hg for 1 min
Number of subjects: 82
Study 1731546 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo with tourniquet
Number of subjects: 82
Study 6748177 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of zinc sulfate daily for eight weeks
Number of subjects: 44
Study 6748177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 29961562 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate
Number of subjects: 378
Study 29961562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study 27554507 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured preoperative phone call 2 to 3 weeks prior to surgery (Group B)
Number of subjects: 43
Study 27554507 — intervention group
Group type: COMPARATOR
Intervention: Conventional consent process by consultant surgeon (Group A)
Number of subjects: 43
Study 26278425 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rosuvastatin daily from preoperative day 7 to postoperative day 28
Number of subjects: 50
Study 26278425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 23616503 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain (WG) diet (150 g/d)
Number of subjects: 17
Study 23616503 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-grain (WG) diet
Number of subjects: 17
Study 23616503 — intervention group
Group type: COMPARATOR
Intervention: Refined grain (RG) diet
Number of subjects: 17
Study 20173541 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic choroid plexus cauterization (ECPC)
Number of subjects: 17
Study 20173541 — intervention group
Group type: COMPARATOR
Intervention: Ventriculoperitoneal shunt (VPS)
Number of subjects: 17
Study 18219250 — intervention group
Group type: EXPERIMENTAL
Intervention: proxy-patient perspective
Number of subjects: 224
Study 18219250 — intervention group
Group type: EXPERIMENTAL
Intervention: proxy-proxy perspective
Number of subjects: 224
Study 16966684 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic responders (defined as a decrease in metabolic activity of the primary tumor by more than 35%)
Number of subjects: 65
Study 16966684 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic nonresponders
Number of subjects: 65
Study 16966684 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic response
Number of subjects: 65
Study 15273016 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual exposure to women (in person or within photographs)
Number of subjects: 0
Study 15273016 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10826509 — intervention group
Group type: COMPARATOR
Intervention: 5 kb deletion in failing hearts (CHF)
Number of subjects: 33
Study 10826509 — intervention group
Group type: COMPARATOR
Intervention: 7.4 kb deletion in failing hearts (CHF)
Number of subjects: 33
Study 10826509 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 kb deletion in ventricles of older persons (> 35 yrs)
Number of subjects: 33
Study 10826509 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.4 kb deletion in ventricles of older persons (> 35 yrs)
Number of subjects: 33
Study 10826509 — intervention group
Group type: EXPERIMENTAL
Intervention: mtDNA amount in left ventricle
Number of subjects: 33
Study 9104663 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous PCA
Number of subjects: 73
Study 9104663 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injections (IM)
Number of subjects: 73
Study 8240927 — intervention group
Group type: EXPERIMENTAL
Intervention: (R,S)-atenolol 100 mg
Number of subjects: 12
Study 8240927 — intervention group
Group type: EXPERIMENTAL
Intervention: (R)-atenolol 50 mg
Number of subjects: 12
Study 8240927 — intervention group
Group type: EXPERIMENTAL
Intervention: (S)-atenolol 50 mg
Number of subjects: 12
Study 2946975 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline 75 mg
Number of subjects: 0
Study 2946975 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline 150 mg
Number of subjects: 0
Study 2946975 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg
Number of subjects: 0
Study 2946975 — intervention group
Group type: EXPERIMENTAL
Intervention: Zimelidine 200 mg
Number of subjects: 0
Study 2946975 — intervention group
Group type: EXPERIMENTAL
Intervention: Indalpine 25 mg
Number of subjects: 0
Study 2946975 — intervention group
Group type: EXPERIMENTAL
Intervention: Indalpine 50 mg
Number of subjects: 0
Study 31640317 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine mouth rinse (CAF) - 25 ml of mint syrup with 1.2% of CAF, equivalent to 300 mg of CAF
Number of subjects: 10
Study 31640317 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA) - 25 ml of mint syrup without CAF
Number of subjects: 10
Study 30202945 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 1709
Study 26329293 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PRD) 40 mg/m²/day
Number of subjects: 32
Study 26329293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTX) 10 mg/kg/day with PRD
Number of subjects: 32
Study 26329293 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal bone marrow)
Number of subjects: 32
Study 24331154 — intervention group
Group type: EXPERIMENTAL
Intervention: Tecemotide (806 μg lipopeptide) administered weekly for 8 weeks, then every 6 weeks until disease progression or withdrawal.
Number of subjects: 829
Study 24331154 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered weekly for 8 weeks, then every 6 weeks until disease progression or withdrawal.
Number of subjects: 829
Study 23016882 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenon
Number of subjects: 256
Study 23016882 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 256
Study 20414680 — intervention group
Group type: EXPERIMENTAL
Intervention: Precut technique
Number of subjects: 6
Study 20414680 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 6
Study 18056501 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal Spine System
Number of subjects: 129
Study 18056501 — intervention group
Group type: COMPARATOR
Intervention: Moss Miami system
Number of subjects: 129
Study 18056501 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon satisfaction with Universal Spine System
Number of subjects: 129
Study 16120857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive belatacept
Number of subjects: 0
Study 16120857 — intervention group
Group type: EXPERIMENTAL
Intervention: Less-intensive belatacept
Number of subjects: 0
Study 16120857 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 0
Study 16120857 — intervention group
Group type: EXPERIMENTAL
Intervention: Belatacept (both regimens)
Number of subjects: 0
Study 11777260 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 months of once‐weekly topical amorolfine lacquer + 6 weeks of oral terbinafine (250 mg once daily)
Number of subjects: 147
Study 11777260 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 months of once‐weekly topical amorolfine lacquer + 12 weeks of oral terbinafine (250 mg once daily)
Number of subjects: 147
Study 11777260 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of oral terbinafine (250 mg once daily)
Number of subjects: 147
Study 9108791 — intervention group
Group type: EXPERIMENTAL
Intervention: 4G allele and homozygous 4G4G genotype associated with high PAI‐1 levels in centenarians
Number of subjects: 254
Study 9108791 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (young, healthy individuals)
Number of subjects: 254
Study 8510064 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative treatments including drug therapy and counselling
Number of subjects: 0
Study 3479012 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 71
Study 3479012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 3479012 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 71
Study 28890996 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG vaccination
Number of subjects: 158
Study 28890996 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 158
Study 27356786 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation group (vertebral artery tortuosity)
Number of subjects: 60
Study 27356786 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vertebral artery tortuosity)
Number of subjects: 60
Study 24164961 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion
Number of subjects: 9
Study 24164961 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 21503940 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir 1.0 mg daily
Number of subjects: 191
Study 18690353 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg loading dose followed by 75 mg daily) and Aspirin (75-325 mg daily for at least six months)
Number of subjects: 3719
Study 18690353 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and Aspirin
Number of subjects: 3719
Study 16491004 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined phototherapy
Number of subjects: 140
Study 16491004 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic Wallaby
Number of subjects: 140
Study 16491004 — intervention group
Group type: COMPARATOR
Intervention: Fiberoptic Biliblanket
Number of subjects: 140
Study 16491004 — intervention group
Group type: COMPARATOR
Intervention: Conventional phototherapy
Number of subjects: 140
Study 12930422 — intervention group
Group type: EXPERIMENTAL
Intervention: Orchidectomy plus lycopene (OL)
Number of subjects: 54
Study 10698138 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction attempts (hyperpronation and supination/flexion)
Number of subjects: 136
Study 10698138 — intervention group
Group type: COMPARATOR
Intervention: Radiographs for patients who failed reduction attempts
Number of subjects: 136
Study 10698138 — intervention group
Group type: COMPARATOR
Intervention: Nonclassic history for mechanism of injury
Number of subjects: 136
Study 9302132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil injections 3 times per week for 12 weeks
Number of subjects: 30
Study 9302132 — intervention group
Group type: COMPARATOR
Intervention: Observation without any erectogenic treatment
Number of subjects: 30
Study 9302132 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprostadil injections
Number of subjects: 30
Study 8377686 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated aspirin (100 mg daily)
Number of subjects: 140
Study 8377686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 3118730 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac 75 mg intramuscularly
Number of subjects: 0
Study 3118730 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3118730 — intervention group
Group type: COMPARATOR
Intervention: Control groups
Number of subjects: 0
Study 3118730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 29954336 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 300
Study 29954336 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 300
Study 27504845 — intervention group
Group type: COMPARATOR
Intervention: Oral health counseling
Number of subjects: 300
Study 27504845 — intervention group
Group type: COMPARATOR
Intervention: Oral health counseling and fluoride varnish
Number of subjects: 300
Study 27504845 — intervention group
Group type: EXPERIMENTAL
Intervention: Control (no preventive intervention)
Number of subjects: 300
Study 24518002 — intervention group
Group type: EXPERIMENTAL
Intervention: High Five intervention
Number of subjects: 445
Study 24316936 — intervention group
Group type: EXPERIMENTAL
Intervention: PD-WEBB training
Number of subjects: 0
Study 24316936 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 20008946 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine monotherapy (20 mg/day)
Number of subjects: 105
Study 20008946 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day) plus Fluoxetine (20 mg/day)
Number of subjects: 105
Study 20008946 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day) plus Venlafaxine (225 mg/day titrated in 14 days)
Number of subjects: 105
Study 20008946 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (30 mg/day) plus Bupropion (150 mg/day)
Number of subjects: 105
Study 18833043 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) concentration of 1.6%
Number of subjects: 100
Study 18833043 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) concentration of 2%
Number of subjects: 100
Study 21050763 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip muscle fatigue
Number of subjects: 28
Study 21050763 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle muscle fatigue
Number of subjects: 28
Study 21050763 — intervention group
Group type: COMPARATOR
Intervention: Control (no fatigue)
Number of subjects: 28
Study 16186422 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmonella typhi vaccination
Number of subjects: 100
Study 16186422 — intervention group
Group type: COMPARATOR
Intervention: Aspirin pretreatment (1200 mg PO)
Number of subjects: 100
Study 11900105 — intervention group
Group type: EXPERIMENTAL
Intervention: Strategic regulation of grain size in memory reporting
Number of subjects: 0
Study 9587726 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thermodilution technique (averaging mode for the previous 6 min)
Number of subjects: 24
Study 9587726 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous thermodilution technique (averaging mode for the previous 3 min)
Number of subjects: 24
Study 9587726 — intervention group
Group type: COMPARATOR
Intervention: Continuous thermodilution technique
Number of subjects: 24
Study 9587726 — intervention group
Group type: COMPARATOR
Intervention: Intermittent bolus technique
Number of subjects: 24
Study 8057708 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrostimulated acupuncture (EA)
Number of subjects: 24
Study 8057708 — intervention group
Group type: COMPARATOR
Intervention: Superficial needle position (SNP) acupuncture
Number of subjects: 24
Study 8057708 — intervention group
Group type: COMPARATOR
Intervention: Control (SNP)
Number of subjects: 24
Study 2459540 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (10 to 40 mg twice daily, increased every 4 weeks)
Number of subjects: 14
Study 2459540 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 29663982 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg nicotine mini lozenge
Number of subjects: 0
Study 29663982 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29663982 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg nicotine mini lozenge
Number of subjects: 0
Study 27059056 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemoadsorption (HA) using CytoSorb™
Number of subjects: 37
Study 27059056 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 37
Study 25691502 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% ascending breath alcohol concentration (BrAC)
Number of subjects: 0
Study 25691502 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.08% peak breath alcohol concentration (BrAC)
Number of subjects: 0
Study 25691502 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% descending breath alcohol concentration (BrAC)
Number of subjects: 0
Study 25691502 — intervention group
Group type: COMPARATOR
Intervention: Compensatory Tracking Task, Digit Symbol Substitution Test, Brief Stop Signal Task, Inspection Time Task
Number of subjects: 0
Study 24308890 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based obesity prevention programme (multiple computer aided telephone counselling interviews)
Number of subjects: 303
Study 24308890 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based obesity prevention programme
Number of subjects: 303
Study 20496731 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint sticking of Wuzhuyu (Evodia Rutaecarpa) at Neiguan (PC 6) and Xinshu (BL 15), once each day for 4 weeks.
Number of subjects: 60
Study 20496731 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Xinbao pills, 3 pills each time, thrice each day for 4 weeks.
Number of subjects: 60
Study 17653617 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft hip protectors
Number of subjects: 1236
Study 17653617 — intervention group
Group type: COMPARATOR
Intervention: Hard hip protectors
Number of subjects: 1236
Study 16612259 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine withdrawal (n = 12)
Number of subjects: 24
Study 16612259 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine continuation (n = 12)
Number of subjects: 24
Study 12759717 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine infusion (0.15 microg/kg/min continuously)
Number of subjects: 6
Study 12759717 — intervention group
Group type: COMPARATOR
Intervention: Isoprenaline infusion (3.5‐35 ng/kg/min)
Number of subjects: 6
Study 12759717 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline infusion (25‐150 ng/kg/min)
Number of subjects: 6
Study 12759717 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline infusion (20‐160 ng/kg/min)
Number of subjects: 6
Study 12759717 — intervention group
Group type: COMPARATOR
Intervention: Bicycle exercise in supine position
Number of subjects: 6
Study 10793322 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil (initially 3 mg per day, increased to 5, 7, and 10 mg per day as needed)
Number of subjects: 133
Study 10793322 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 133
Study 8678327 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic diffuse atherosclerosis
Number of subjects: 4159
Study 8678327 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 4159
Study 8678327 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 4159
Study 8678327 — intervention group
Group type: EXPERIMENTAL
Intervention: History of multiple myocardial infarctions
Number of subjects: 4159
Study 8678327 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 4159
Study 8678327 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 4159
Study 8678327 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced exercise performance
Number of subjects: 4159
Study 8678327 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smoking status
Number of subjects: 4159
Study 8678327 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower alcohol intake
Number of subjects: 4159
Study 1814249 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% prilocaine with 1:200,000 epinephrine
Number of subjects: 30
Study 1814249 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% mepivacaine with 1:20,000 levonordefrin
Number of subjects: 30
Study 1814249 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 30
Study 6347741 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-aggressive management (study group)
Number of subjects: 156